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Abstract
Background: In colon cancer patients, obesity, sedentary lifestyle, and high dietary glycemic load have been associated with
increased risk of cancer recurrence. High sugar-sweetened beverage intake has been associated with obesity, diabetes, and
cardio-metabolic diseases, but the influence on colon cancer survival is unknown.
Methods: We assessed the association between sugar-sweetened beverage consumption on cancer recurrence and
mortality in 1,011 stage III colon cancer patients who completed food frequency questionnaires as part of a U.S. National
Cancer Institute-sponsored adjuvant chemotherapy trial. Hazard ratios (HRs) and 95% confidence intervals (CIs) were
calculated with Cox proportional hazard models.
Results: Patients consuming $2 servings of sugar-sweetened beverages per day experienced an adjusted HR for disease
recurrence or mortality of 1.67 (95% CI, 1.04–2.68), compared with those consuming ,2 servings per month (Ptrend=0.02).
The association of sugar-sweetened beverages on cancer recurrence or mortality appeared greater among patients who
were both overweight (body mass index $25 kg/m
2) and less physically active (metabolic equivalent task-hours per week ,
18) (HR=2.22; 95% CI, 1.29–3.81, Ptrend=0.0025).
Conclusion: Higher sugar-sweetened beverage intake was associated with a significantly increased risk of cancer recurrence
and mortality in stage III colon cancer patients.
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Introduction
Increasing evidence indicates that excess energy balance,
including obesity, sedentary lifestyle, and high intake of a Western
pattern diet, is associated with an increased risk of developing
colon cancer. [1–4] One hypothesis explaining these observations
has been the role of hyperinsulinemia in promoting cancer
development and progression. [5,6] Prospective studies demon-
strate associations between colon cancer risk among individuals
with diabetes or elevated circulating levels of insulin or C-peptide.
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e99816[6–8] Beyond cancer risk, observational studies of colon cancer
patients suggest that these same host factors, including obesity,
sedentary lifestyle, high intake of a Western pattern diet, and high
dietary glycemic load confer an increased risk of colon cancer
recurrence [9–11].
Across numerous studies, higher intake of sugar-sweetened
beverages has been associated with an increased risk of obesity,
type 2 diabetes, and related cardio-metabolic diseases. [12–17]
Consumption of sugar-sweetened beverages has increased in the
U.S. over the past 3 decades; per capita consumption in 2009 was
estimated at 45 gallons per year, or nearly half of total beverage
intake. [18] Worldwide, sugar-sweetened beverages have been
associated with 180,000 deaths annually. [19] Nonetheless, the
influence of sugar-sweetened beverage intake on colon cancer risk
or colon cancer patient outcomes remains largely unknown.
In light of the emerging evidence supporting a link between
excess energy balance, hyperinsulinemia and inferior survival in
colon cancer patients, we prospectively examined the impact of
sugar-sweetened beverage intake on cancer recurrence and
mortality in a cohort of stage III colon cancer patients enrolled
in a National Cancer Institute-sponsored adjuvant chemotherapy
clinical trial. We prospectively collected extensive data on diet and
lifestyle prior to any documentation of cancer recurrence.
Materials and Methods
Study Population
Patients in this prospective cohort participated in the National
Cancer Institute–sponsored Cancer and Leukemia Group B
(CALGB, now Alliance for Clinical Trials in Oncology) 89803
adjuvant therapy trial for stage III colon cancer, comparing
therapy with weekly 5-fluorouracil and leucovorin to weekly
irinotecan, 5-fluorouracil, and leucovorin (ClinicalTrials.gov
NCT000038350). [20] Between May 1999 and May 2001, 1,264
patients were enrolled in the treatment trial. After 87 patients were
enrolled, an amendment required patients to complete a self-
administered questionnaire that captured diet and lifestyle habits
midway through their therapy (4 months after surgery; question-
naire 1 [Q1]) and again 6 months after completion of treatment
(14 months after surgery; Q2).
Patients were eligible if they underwent a complete surgical
resection of the primary tumor within 56 days of trial entry, had
regional lymph node metastases but no evidence of distant
metastases, had a baseline Eastern Cooperative Oncology Group
performance status of 0 to 2, [21] and had adequate bone marrow,
renal, and hepatic function. Figure 1 illustrates the derivation of
the final sample size of 1,011 patients for this study. We previously
demonstrated that there were no appreciable differences in
baseline characteristics between the 1,011 patients who were
eligible for this analysis and the remaining 253 patients enrolled in
CALGB 89803 not included in the dietary analysis. [22] All
patients signed informed consent, which was approved by the
National Cancer Institute’s Cancer Treatment Evaluation Pro-
gram (CTEP) as well as each participating site’s institutional
review board (IRB), including the Dana-Farber/Harvard Cancer
Center IRB.
Dietary Assessment
Patients in this analysis completed semi-quantitative food
frequency questionnaires (FFQs) that included 131 food items,
vitamin and mineral supplements, and open-ended sections for
other supplements and foods not specifically listed. [23,24]
Participants were asked how often, on average over the previous
3 months, they consumed a specific food portion size, with up to
nine possible responses, which ranged from never to six or more
times per day. We computed nutrient intakes by multiplying the
frequency of consumption of each food by the nutrient content of
the specified portions using composition values from Department
of Agriculture sources supplemented with other data [25] All
nutrient values were energy-adjusted using the residuals methods
[26].
On each FFQ, patients reported on their usual daily or weekly
intake of a standard 355-mL (12-ounce) serving (1 glass, can, or
bottle) of sugar-sweetened caffeinated colas, caffeine-free colas,
other carbonated sugar-sweetened beverages, and noncarbonated
sugar-sweetened beverages (fruit punches, lemonades, or other
fruit drinks). We summed the consumption of these beverages as
total sugar-sweetened beverages. In other cohort studies, the
reproducibility and validity of our FFQ in measuring sugar-
sweetened beverages was previously described: the Pearson
correlation coefficient, corrected for within-person variation,
between the FFQ and separate dietary records was 0.84 for cola
and 0.36–0.40 for non-cola soda [27] In addition, we separately
validated this FFQ among cancer patients receiving chemotherapy
[28].
Patients who completed Q1 and whose cancer had not recurred
prior to Q1 completion were included in these analyses. The
median time from study entry to Q1 was 3.5 months (95% range,
2.5–5.0 months; full range, 0.2–9.9 months). To avoid potential
biases due to declining health immediately before cancer
recurrence or death, we excluded patients who experienced
cancer recurrence or death within 90 days following completion of
Q1 (Figure 1). We calculated dietary exposures based on the
results of the Q2 using cumulative averaging as previously
described,[29] but weighted proportional to times between Q1
and Q2 and then between Q2 and disease-free survival time. For
example, if a patient completed Q1 at 4 months, completed Q2 at
14 months, and had a cancer recurrence at 30 months, the total
time between Q1 and cancer recurrence was 26 months and 38%
of that time was between Q1 and Q2 and 62% of that time was
between Q2 and the recurrence.
Study Endpoints
The primary end point of our study was disease-free survival,
defined as time from the completion of the Q1 to tumor
recurrence, occurrence of a new primary colon tumor, or death
from any cause. We also assessed recurrence-free survival, defined
as the time from the completion of Q1 to tumor recurrence or
occurrence of a new primary colon tumor. For recurrence-free
survival, patients who died without known tumor recurrence were
censored at last documented evaluation by treating physician.
Finally, overall survival was defined as the time from the
completion of Q1 to death from any cause.
Statistical Analysis
Sugar-sweetened beverage intake was classified by frequency of
12-ounce servings: less than 2 per month (reference), 2 per month
to 2 per week, 3 to 6 per week, 1 per day to less than 2 per day,
and 2 or more per day. Cox proportional hazards regression was
used to determine the simultaneous impact of other variables
potentially associated with each outcome. [30] As previously
described, [26] all analyses of sugar-sweetened beverage intake
were adjusted for total caloric intake to assess the effect of sugar-
sweetened beverages independent of total energy intake. We
further used time-varying covariates to adjust for total calories,
physical activity (measured in metabolic equivalent tasks [MET]-
hours per week), [31] body mass index (BMI, calculated as weight
in kilograms divided by height in meters squared), and consump-
Sugar-Sweetened Beverages and Colon Cancer Survival
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the second questionnaire. Other covariates (including age at study
entry, gender, number of positive lymph nodes, depth of invasion
through bowel wall, baseline performance status, and treatment
group) were also entered into the model as fixed covariates. In
secondary multivariate analyses, we further adjusted for dietary
Figure 1. Derivation of the study cohort. Q1=question 1 (midway through adjuvant therapy); Q2=questionnaire 2 (6 months after completion
of adjuvant therapy). Caloric intake exclusion=Less than 600 calories or greater than 4,200 calories per day for men and less than 500 calories or
greater than 3,500 calories per day for women.
doi:10.1371/journal.pone.0099816.g001
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with indicator variables in adjusted models. We tested for linear
trends across categories of sugar-sweetened beverages by assigning
each participant the median value for each category and modeling
this value as a continuous variable, consistent with prior studies.
[10,22] In subgroup exploratory analyses, the five intake
categories were collapsed (1 and 2; 3 and 4; 5) to conserve power
to create 3 groupings with practical meaning – less than twice a
week, several times per week to daily and more than 2 per day.
The Cox regression models met the assumption of proportionality.
A level of significance ,0.05 was considered statistically signifi-
cant. All P values are 2-sided and were not adjusted for multiple
comparisons.
Patient registration and clinical data collection were managed
and analyses were conducted by the Alliance Statistics and Data
Center. All analyses were based on the study database frozen on
November 9, 2009.
Results
Study participants were drawn from a multicenter study of
adjuvant chemotherapy after surgery in patients with stage III
colon cancer. Baseline characteristics by level of sugar-sweetened
beverage consumption are shown in Table 1. Patients consuming
greater quantities of sugar-sweetened beverages were younger and
more likely to be male and had a higher intake of a Western
pattern diet and dietary glycemic load.
The median follow-up from the time of completion of Q1 was
7.3 years. In total, 343 of the 1,011 patients included in this
analysis had cancer recurrence; 262 of these 343 patients died. An
additional 43 patients died without documented cancer recur-
rence.
The pre-defined primary endpoint of our analysis was disease-
free survival. Increasing consumption of sugar-sweetened bever-
ages was associated with a greater risk of cancer recurrence or
mortality after adjusting for other predictors of cancer recurrence
(Table 2). Compared to patients who drank less than two sugar-
sweetened beverage per month, consumers of 2 or more servings
per day experienced an adjusted hazard ratio (HR) for disease
recurrence or mortality of 1.67 (95% confidence interval
[CI]=1.04–2.68; Ptrend=0.02). These results were largely un-
changed when we further adjusted for dietary glycemic load in the
multivariate model (Ptrend=0.03).
To isolate the influence of sugar-sweetened beverage intake on
cancer recurrence, we assessed the endpoint of recurrence-free
survival and confirmed that higher intake of sugar-sweetened
beverage conferred a significantly increased risk in cancer
recurrence (Ptrend=0.02; Table 2). Patients consuming 2 or more
servings per day were 1.84 times more likely to recur than those
who largely abstained. We observed a trend toward greater overall
mortality with consumption of 2 or more sugar-sweetened
beverages per day, although the results were not statistical
significant (Ptrend=0.12).
Taking into account the possibility that dietary changes could
reflect occult cancer or imminent death, we excluded patients who
developed cancer recurrence or died within 90 days of completing
Q1 in our initial analyses. To further explore the potential
influence of occult cancer or imminent death, we excluded 44
patients who developed cancer or died within 180 days of
completing Q1; our results remained largely unchanged. Increas-
ing sugar-sweetened beverage intake was associated with an
inferior disease-free survival (Ptrend=0.04) and an inferior
recurrence-free survival (Ptrend=0.04).
We explored whether the association between sugar-sweetened
beverage intake and patient outcome differed between individual
sugar-sweetened beverages subtypes (colas; other carbonated
beverages; and non-carbonated fruit drink and punches). The
association between consumption of specific sugar-sweetened
beverages and survival endpoints did not differ between beverage
subtypes; tests for heterogeneity between subtypes was not
statistically significant for disease-free survival (P=0.65), recur-
rence-free survival (P=0.59), or overall survival (P=0.71), though
power for these analyses is limited.
We also examined the influence of sugar-sweetened beverage
intake on disease-free survival across strata of other potential
predictors of patient outcome (Figure 2), using three categories of
intake (2 or less beverages per week, between 3 beverages per week
and less than 2 per day and 2 or more beverages per week). In the
forest plot, we demonstrate the hazard ratio comparing the two
extreme categories. The association of sugar-sweetened beverage
intake was not significantly modified by any potential predictors of
patient outcome.
We further explored whether the association between sugar-
sweetened beverage intake and the risk for cancer recurrence or
mortality was more pronounced among patients who were both
overweight (BMI$25 kg/m
2) and less physically active (,18
MET-hours/week) (Figure 3). Among patients who were both
overweight and less active (n=541), the adjusted HR for cancer
recurrence or mortality was 2.22 (95% CI, 1.29–3.81) when
comparing the highest and the lowest categories of sugar-
sweetened beverage intake (Ptrend=0.0025). In contrast, among
the 84 patients who were both normal weight (,25 kg/m
2) and
physically active (MET-hours per week $18), sugar-sweetened
beverage intake did not significantly influence the risk of cancer
recurrence or mortality (Ptrend=0.67). A test for statistical
interaction between sugar-sweetened beverage intake and the
combined assessment of BMI and physical activity was, however,
not significant (Pinteraction=0.40).
Discussion
In this cohort of stage III colon cancer patients enrolled in a
clinical trial of postoperative adjuvant chemotherapy, increased
intake of sugar-sweetened beverages was associated with a
significantly increased risk of cancer recurrence or mortality, and
the deleterious association of sugar-sweetened beverages was
largely confined to patients who consumed 2 or more servings per
day. The association between sugar-sweetened beverage con-
sumption and patient outcome was independent of other measures
of energy balance, including body-mass index, Western pattern
diet, and dietary glycemic load.
To our knowledge, no previous study has examined the
association of sugar-sweetened beverage intake on clinical
outcome in patients with established colon cancer. Two studies
have examined the relation between sugar-sweetened beverage
intake and the risk of developing colon cancer, and the results have
been inconsistent. [32,33] In otherwise healthy cohorts, sugar-
sweetened beverages have been linked with weight gain, diabetes,
hypertension, hyperlipidemia, gout, and coronary artery disease.
[13–17,34,35] In randomized clinical trials, replacement of sugar-
containing beverage with a sugar-free beverage significantly
reduced weight gain and fat accumulation in children and
adolescents. [36,37] In a recent observational study of healthy
adults, the association between sugar-sweetened beverage and
obesity was significantly greater in subjects with a genetic
predisposition to obesity. [38] Interestingly, sugar-sweetened
beverage intake was associated with significant increase in cancer
Sugar-Sweetened Beverages and Colon Cancer Survival
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overweight and less physically active, whereas there did not
appear to be an association among patients who were normal
weight and physically active.
Previous observational studies of colon cancer patients have
observed increased risks of cancer recurrence or mortality in
association with a history of type 2 diabetes, obesity, sedentary
lifestyle, high Western pattern diet, and greater dietary glycemic
load. [9–11] While the mechanisms accounting for these
observations remain uncertain, chronic hyperinsulinemia, pro-
moting increased cancer cell proliferation and reduced apoptosis,
has been proposed as one putative explanation. [39–42] In support
of the hypothesis, higher circulating C-peptide was associated with
increased cancer mortality in a population of stage I–III colorectal
cancer patients [11].
Table 1. Baseline characteristics of 1,011 patients by consumption level of sugar-sweetened beverage consumption*.
Consumption level
,2/mo 2/mo to 2/wk 3 to 6/wk 1 to ,2/d $2/d
(n=212) (n=355) (n=258) (n=115) (n=71)
Median 0.5/mo 5.5/mo 4.6/wk 1.3/d 2.6/d
Age, median (range), years 63.0 (32–85) 63.0 (28–83) 58.0 (24–81) 57.0 (21–80) 51.0 (27–74)
Male, No (%) 93 (43.9) 187 (52.7) 162 (62.8) 72 (62.6) 55 (77.5)
Race, No (%)
White 195 (92.0) 323 (91.0) 226 (87.6) 97 (84.3) 58 (81.7)
Black 5 (2.3) 16 (4.5) 19 (7.4) 14 (12.2) 11 (15.5)
Other 12 (5.7) 16 (4.5) 13 (5.0) 4 (3.5) 2 (2.8)
Baseline performance status, No. (%)
`
0 157 (74.1) 263 (74.1) 194 (75.2) 79 (68.7) 49 (69.0)
1–2 49 (23.1) 86 (24.2) 61 (23.6) 31 (27.0) 21 (29.6)
Status unknown 6 (2.8) 6 (1.7) 3 (1.2) 5 (4.3) 1 (1.4)
Invasion through bowel wall by T stage, No. (%)
¥
T1–2 29 (13.7) 54 (15.2) 29 (11.2) 13 (11.3) 11 (15.5)
T3–4 169 (79.7) 283 (79.7) 210 (81.4) 89 (77.4) 56 (78.9)
T stage unknown 14 (6.6) 18 (5.1) 19 (7.4) 13 (11.3) 4 (5.6)
Positive lymph nodes, No. (%)
1–3 141 (66.5) 229 (64.5) 166 (64.3) 58 (50.4) 41 (57.8)
$4 65 (30.7) 121 (34.1) 90 (34.9) 52 (45.2) 28 (39.4)
Nodes unknown 6 (2.8) 5 (1.4) 2 (0.8) 5 (4.4) 2 (2.8)
Grade of differentiation, No. (%)
Well 18 (8.5) 13 (3.6) 17 (6.6) 5 (4.3) 4 (5.7)
Moderate 140 (66.0) 259 (73.0) 178 (69.0) 75 (65.3) 49 (69.0)
Poor/Undifferentiated 48 (22.7) 76 (21.4) 61 (23.6) 30 (26.1) 17 (23.9)
Grade unknown 6 (2.8) 7 (2.0) 2 (0.8) 5 (4.3) 1 (1.4)
Clinical bowel obstruction at presentation, No. (%) 43 (20.3) 77 (21.7) 56 (21.7) 29 (25.2) 17 (23.9)
Bowel perforation at presentation, No. (%) 9 (4.2) 12 (3.4) 17 (6.6) 2 (1.7) 3 (4.2)
Treatment arm, No. (%)
5-FU/LV 104 (49.1) 180 (50.7) 136 (52.7) 57 (49.6) 36 (50.7)
IFL 108 (50.9) 175 (49.3) 122 (47.3) 58 (50.4) 35 (49.3)
Body mass index, median (range), kg/m
21{ 27.0 (17–50) 27.2 (18–52) 27.4 (16–49) 27.3 (16–46) 28.0 (17–50)
Physical activity, median (range) MET h/wk
1% 4.6 (0–125) 4.1 (0–90) 6.0 (0–125) 6.3 (0–147) 4.2 (0–113)
Western dietary pattern, No. ,median (%)
1 81 (38.2) 170 (47.9) 147 (57.0) 80 (69.6) 57 (80.3)
Prudent pattern diet, No. ,median, (%)
1 134 (63.2) 191 (53.8) 113 (43.8) 44 (38.3) 30 (42.3)
Dietary glycemic load
1 138.2 (58–221) 143.0 (75–232) 147.2 (89–211) 163.4 (94–247) 168.3 (123–231)
Mo=month; No.=number; 5-FU=5-fluorouracil; IFL=irinotecan, 5-fluorouracil, leucovorin; LV=leucovorin; MET=metabolic equivalent tasks.
`Baseline performance status: PS 0=fully active; PS 1=restricted in physically strenuous activity but ambulatory and able to carry out light work; PS 2=ambulatory and
capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours.
¥T1–2=level of invasion through the bowel wall not beyond the muscle layer; T3–4=level of invasion through the bowel wall beyond the muscle layer.
1Based on questionnaire 1.
{1 subject is missing body mass index in questionnaire 1.
%6 subjects are missing physical activity in quesitonnaire 1.
doi:10.1371/journal.pone.0099816.t001
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PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e99816Sugar-sweetened beverages provide a high caloric content with
low satiety and incomplete compensation for these liquid calories,
resulting in an increased total energy intake. [43,44] In addition,
because of the large amounts of rapidly absorbable carbohydrates
in sugar-sweetened beverages, greater consumption may increase
the risks of insulin resistance, beta-cell dysfunction, inflammation,
visceral adiposity, and other metabolic disorders. [13,45] In a
prior analysis of our colon cancer patient cohort, neither total
sucrose nor fructose intake was significantly associated with patient
outcome. [22] Nonetheless, sucrose or fructose from beverages and
processed foods (e.g., sweets, cookies) are more rapidly absorbed
and may have a greater detrimental effect than sugars from fruit or
other natural sources [13,45].
Our analysis in patients treated within a U.S. National Cancer
Institute–sponsored clinical trial provided several advantages. All
patients had lymph node–positive, non-metastatic cancer at study
entry, reducing the impact of heterogeneity by disease stage.
Treatment and patient follow-up were carefully prescribed in the
trial, and the date and nature of cancer recurrence were
prospectively recorded through regular detailed medical exami-
nations. Detailed information on other potentially confounding
prognostic variables was also prospectively collected at study entry.
Finally, we updated dietary data to reflect changes in diet that may
have occurred after patients had completed adjuvant therapy and
recovered from treatment effects. Repeated dietary intake data
served to reduce random measurement error, and any residual
random error would likely lead to an underestimate of the true
effect of exposures with outcome.
Nonetheless, we do recognize limitations within our analysis.
Patients who enroll in randomized trials may differ from the
population at large. However, the distribution of dietary intake
and lifestyle factors in our cohort was consistent with other U.S.
cohort studies. [46] Moreover, since the study included patients
from community and academic centers throughout North
America, our findings should reflect the general population.
We cannot completely exclude the possibility that increased
sugar-sweetened beverage consumption may simply reflect other
predictors of poor cancer prognosis. However, the effect of sugar-
sweetened beverage was independent of other known or suspected
prognostic factors, and our results remained largely unchanged
when we further adjusted for other energy balance factors,
including BMI, physical activity, Western and prudent pattern
Figure 2. Multivariate hazard ratios and 95% CI for cancer recurrence and mortality across strata of various factors. Analyses utilized
3 categories (2 or less servings per week, between 3 servings per week and less than 2 servings per day and 2 or more serving per day. The forest plot
represents the hazard ratios of the comparison of $2 servings per day of sugar-sweetened beverage intake to #2 serving per week. No.=Number;
y=years; kg=kilograms; m=meters; wk=weeks; 5-FU/LV=5-fluorouracil/leucovorin; IFL=bolus 5-fluorouracil, leucovorin, and irinotecan.
doi:10.1371/journal.pone.0099816.g002
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PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e99816diets, and dietary glycemic load. Further, the detrimental effect of
sugar-sweetened beverage intake persisted across strata of prog-
nostic variables and dietary/lifestyle factors. Nevertheless, because
of the observational nature of this study, we cannot exclude the
possibility of residual and unmeasured confounding variable.
Finally, while the original companion study for CALGB 89803 did
pre-specify analyses of associations of dietary factors associated
with energy balance and outcomes, caution should also be
exercised when interpreting studies with multiple comparisons
and P values.0.01. However, the point estimates are consistent
across strata, and results are consistent with other analyses of
energy balance in this cohort. [10,22,47,48] Nonetheless, these
results require confirmation in other cohorts.
We considered the possibility that patients with either occult
cancer recurrences or other statistically significant poor prognostic
characteristics may have increased their sugar-sweetened beverage
intake as an alternative source of needed calories. To minimize
this bias, we excluded recurrences or deaths within 90 days of FFQ
completion. When we extended this restriction to 6 months, we
continued to observe a deleterious association of sugar-sweetened
beverage consumption on patient outcomes. Finally, because
patients on this clinical trial underwent comprehensive staging at
study entry and were followed with prescribed follow-up visits and
testing, we would expect few patients to have undetected
recurrences over extended periods.
Given that patients who consume sugar-sweetened beverages
after cancer diagnosis may have consumed a similar diet before
diagnosis, we cannot exclude the possibility that consumers of
sugar-sweetened beverages develop biologically more aggressive
colon cancers. Nonetheless, we did not observe a meaningful
association between sugar-sweetened beverage intake and tumor-
related characteristics associated with cancer recurrence.
In summary, this prospective analysis, imbedded in a clinical
trial, suggests that increased sugar-sweetened beverage intake is
associated with a significantly worse disease-free and recurrence-
free survival for stage III colon cancer patients. Although our
observational study does not provide conclusive evidence for
causality, these findings support the potential role of sugar-
sweetened beverage intake in colon cancer progression and
potentially offer meaningful recommendations for clinical care.
Further analyses in other cohorts of colon cancer survivors are
needed to confirm these findings.
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